Resistance Mutation Intelligence, 4th-Generation TKI Development, and Selective Screening Reagents for NSCLC Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EGFR T790M drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Antigen | EGFR T790M Recombinant Protein (Kinase Domain, residues 696-1022). High purity (>95%), Endotoxin <1 EU/µg. Sequence verified by mass spec. HEK293 expressed for native folding. | View EGFR T790M Products |
| Wild-Type Control | EGFR (WT) Recombinant Protein (Kinase Domain). Selectivity reference standard. >95% purity, mass spec verified. | View EGFR Products |
| Gene Delivery | EGFR T790M Promise-ORF Lentivirus. Full-length ORF for stable Ba/F3 or HEK293 cell line construction. | View EGFR T790M Products |
| Benchmark Ab | Anti-EGFR (Sequence of Cetuximab). Recombinant positive control for ECD binding assays and WT binding comparison. | View EGFR Products |
| Validator | EGFR siRNA Set. For knockdown verification and specificity checks. | View EGFR T790M Products |
| Next-Gen Resistance | EGFR C797S Mutant Protein. For 4th-gen TKI screening and compound mutation studies (T790M/C797S). | View EGFR C797S Products |
| Bypass Pathway | MET (c-Met) Protein. HGF receptor for resistance mechanism studies (MET amplification bypass). | View MET Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity: T790M vs WT discrimination (Avoiding skin and GI toxicity) | Matched Pair Available: T790M Mutant + WT Proteins with >95% purity for parallel SPR/ITC screening |
| ATP Competition (T790M gatekeeper mutation increases ATP affinity ~20-fold) | High-concentration Active Kinase Domain (696-1022 aa) for ATP-competitive binding assays at physiological ATP levels |
| C797S Compound Mutation Screening (Post-Osimertinib resistance) | T790M/C797S Double Mutant Protein Available; Sequence Verified by NGS |
| Cellular Context Loss (Biochemical assays may not reflect membrane environment) | Lentivirus Particles for Stable Cell Line Generation (Preserved native folding and glycosylation) |
| Lack of Suitable Controls | Clinical Benchmark Antibodies (Cetuximab biosimilar) and matched WT protein included |
| False Positives from Off-Target Effects | Validated siRNA included for specificity checks |
Live EGFR T790M R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The EGFR T790M gatekeeper mutation (Thr790Met) in the protein kinase domain is the primary acquired resistance mechanism to first- and second-generation EGFR TKIs (e.g., gefitinib, erlotinib) in non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso), a third-generation irreversible TKI, has become the standard of care for T790M-positive NSCLC. However, the clinical landscape is rapidly evolving:
- Resistance to 3rd-gen TKIs: The emergence of C797S mutation (tertiary resistance), often in cis with T790M, drives the need for 4th-generation inhibitors and allosteric binders.
- Next-wave modalities: Beyond small-molecule TKIs, research is expanding to PROTACs (protein degraders), bispecific antibodies (e.g., Amivantamab targeting EGFR/MET), and antibody-drug conjugates (ADCs) to overcome bypass resistance mechanisms (e.g., MET amplification, HER2 mutation).
- Triple-mutant challenges: Double (T790M/C797S) and triple (L858R/T790M/C797S) mutants require highly selective compounds that avoid WT EGFR inhibition to limit dose-limiting toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| 3rd Gen TKI (Existing) | AstraZeneca (Osimertinib), Hansoh (Almonertinib), Allist (Furmonertinib) | NSCLC (1st/2nd Line T790M+) | WT/Mutant Selectivity Assay (Need T790M + WT protein pair) |
| 4th Gen TKI | Blueprint Medicines (BLU-945), Black Diamond | T790M/C797S+ NSCLC | Compound Mutant Binding (Need T790M/C797S double mutant protein) |
| PROTAC/Degrader | C4 Therapeutics, Arvinas | Resistant NSCLC | Cell Permeability & Target Engagement (Need Cellular Stable Lines) |
| Bispecific Antibody | Janssen (Amivantamab - EGFR/MET) | EGFR/MET-driven Tumors | Receptor Validation (Need Cross-reactive Abs & Benchmark Controls) |
| ADC | Daiichi Sankyo (HER3-DXd), AstraZeneca | EGFR-driven Solid Tumors | Internalization Assay (Need Full-length ECD expression systems) |